sphingotec reveals novel results on bioactive adrenomedullin for diagnosis and therapy monitoring of septic shock at the 39th International Symposium on Intensive Care and Emergency Medicine (ISICEM) Data from more than 20,000 patients show that bio-ADM® adds value to clinical decision-making at ICUs and EDs because it is the only biomarkerthat allows early prediction of…Read more
Recent Posts by admin
sphingotec announces new data on the kidney function marker proenkephalin (penKid®) presented at 24th International Conference onAdvances in Critical Care Nephrology Medical leaders in renal critical care presented study data at the 24th AKI & CRRT conference supporting the hypothesis that plasma penKid® levels reflect kidney function in critically ill burn patients, heart failure patients,…Read more
Endothelial disruption: Rapid translation from bench to bedside bio-ADM, the very first blood biomarker capable to diagnose when blood vessels become leaky (endothelial dysfunction), is set to make a rapid carrier at intensive care units (ICUs) and emergency departments (EDs) of hospitals. Data from pilot clinical routine testing presented at the 2nd Scientific Symposium on…Read more
Diagnostics company SphingoTec GmbH successfully closed €20 million growth equity financing round led by international specialist investors HBM Healthcare Investments, HBM BioCapital II LP (HBM) and Wellington Partners Proceeds will be used to launch the NEXUS IB 10 point-of-care (POC) platform and the novel acute biomarker blood tests sphingotest® penKid® and sphingotest® bio-ADM® Ability to…Read more
Recent Comments by admin
No comments by admin yet.